Drug Profile
AC 165198
Alternative Names: AC-165198; PhybridLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amylin Pharmaceuticals; Biocon
- Developer Amylin Pharmaceuticals
- Class Hormones; Peptide hormones; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA
- 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity in USA
- 14 Aug 2013 AC 165198 is still in phase I trials for Diabetes mellitus & Obesity